The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.
I’m a long time investor and lurker here, and don’t normally speculate, but the appointment of Christina with a ‘head of’ title rather than Chief …. Officer’ struck me as being a curious move.
Both Neil and Fiona were ‘Chief Officers’ and Christina was previously a CEO who has now been given a wide responsibility at Avacta of ‘ overseeing all clinical development and pre-clinical research activities of the Therapeutics Division’. She is an executive director of the company so at the top in terms of organisational structure.
So here is my (take with a big pinch of salt) speculation. I have personally been part of three medium/small sized companies that were acquired by much, much, much larger conglomerates. In every case, the leadership teams of the acquired companies had to change their ‘chief ….officer’ titles as they would not fit with their acquisition conglomerates’ org structure. You can’t normally have a chief officer in control of a comparatively very small division inside a multi-billion pound corporation. They all had to become Executive Vice Presidents or Senior Vice Presidents or ‘Directors of’ or ‘Heads of’ . You can see where I’m going with this.
Between the appointment of the Chief biz officer and Christina, perhaps there has been serious movement on an acquisition level event. But who can really predict something like that on something as potentially trivial as a title change.
Speculation over.
Looks like a fantastic development.
Can anyone read the formula name and identify it as ava6000?
Just a reminder: Massive push on Cancer treatment from the White House yesterday
https://twitter.com/whitehouse/status/1488965445210316814?s=21
“Today, @POTUS and @FLOTUS are reigniting the Cancer Moonshot and setting new goals to reduce the death rate from cancer by 50% over the next 25 years, and improve the experience of patients and families living with and surviving cancer.”
Thanks for sharing Carlo. It seems to have changed then from the first version - as can be found on twitter screen grabs. My mistake.
Although the dates on that link still say 1st feb so they may have moved that forward from the 2nd again.
All a bit confusing and probably not worth reading too much into.
Very happy to stand corrected, but I would like to know where this misunderstanding has been stated? Genuine question.
Currently I am going off the newsletter sent from Capital Access.
Remember it is advertised as a “post trading update” roadshow.
So post news in other words
Don’t give me hope. I’ve been hurt too many times before.
Positive lft and precision news at the same time.
What a day that would be!
It would make absolutely no sense to update the website with this copy and then release disappointing trial results a day or two later.
Especially when they’re lining up meetings with institutions.
Would make sense for them to cash in their winnings at this price
“damaged parts of the UK-based industry to a point of crisis.”
Surely this is the sort of quote that will make for an engaging press headline. A UK industry body has claimed the gov have brought them to near crisis.
Kamani was involved in that one. Not that it means much to us.
I’m not surprised at these prices.
Vatic will be going through the self test certification process now. They must expect to get it soon to justify such high production volumes. They are partnered with biosure who got self test ce mark for their antibody test so will undoubtedly be helping in that area. Abingdon manufacturers both tests so again there is that connection.
Add onto that the (maybe imminent) AVCT self test ce mark, and you can see how just a few things coming off could boost the share price significantly.
SureScreen are getting some of their government machines adapted. So this is probably not the original approved test. Must be a newer version.
https://bidstats.uk/tenders/2021/W36/758448705
For the first time, I think this might actually be leak!
If not, I officially give up.
* Avacta* - I should really have learnt how to spell that by now lol
Has anyone got any thoughts or snippets of information on Mologic's updated self-test that they announced earlier this year?
https://mologic.co.uk/mologics-covid-19-rapid-antigen-self-test-selected-by-nih-for-radx-initiative-funding/
"Mologic’s independently verified COVID-19 lateral flow technology combines all reagents in a unique design". I think this means it incorporates the buffer into the cassette.
It clearly has a different design to the standard white cassettes seen previously, as the picture in this tweet shows: https://twitter.com/mologic/status/1379474197039214601
And you can see the new design appears in a photo on Mologics' plastics manufacturing partner's website: https://adrecoplastics.co.uk/assembly/
I just think it could be relevant to Avacter as the initial press release states: "Mologic is also making this unique self-test design available to its customers and partners across a broad range of self-test applications, through the company’s contract research & manufacturing programme."
On the flip side, funded by Innova Medical Group
A £10m research centre has been created in Liverpool to prevent, prepare for and respond to future pandemics.
https://www.bbc.co.uk/news/live/uk-58542140
Run by Matthew Baylis, the gentleman who is speaking at Avacta’s industry event
Not checked the site for a while, but the last time I did, AffiDX was not advertised on the home page. https://bioservuk.com/
Nice to see it is now.
Sorry for the double thread, but I couldn't allow the first subject's grammatical mistake to stand.
https://atamis-1928.cloudforce.com/sfc/p/#0O000000rwim/a/4J000000NQBb/xUSuHxdC0e7EHq_OJPmVOLFmyOV_783fSAm9bNl9.g4
https://bidstats.uk/tenders/2021/W35/758120876
Looks like the government are paying bbi solutions to analyse some n protein binding antibodies cooked up by Oxford University, and some Aptamers from Aptamer Group.
The recommended reagents will then be taken forward to ‘prototype development of a lateral flow test.’
This government never ceases to amaze.